



Company Contact:

Rose Alinaya
SVP, Investor Relations
661-775-5300
ir@mannkindcorp.com

MannKind Corporation Reports 2017 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

VALENCIA, Calif., August 7, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial results for the second quarter and the six months ended June 30, 2017. Key results include:

- Completed commercial expansion
- Afrezza net revenue and gross revenue grew 29% and 60%, respectively, vs. Q1 2017
- Reduced Deerfield obligations by \$15 million through equity conversion and cash payments
- Increased cash by \$19.4 million through The Mann Group loan arrangement
- Positive pre-IND meeting with the FDA for treprostinil Technosphere

Second Quarter Results

For the second quarter of 2017, total net revenue of \$2.2 million was comprised of \$1.5 million of Afrezza product net sales, \$0.1 million of collaboration revenues and \$0.6 million of other revenues from the sale of certain oncology intellectual property. As of June 30, 2017, Afrezza product shipped to the wholesale and retail channel, but not yet recognized as revenue, was \$2.6 million. Afrezza net revenue and gross revenue grew 29% and 60%, respectively, compared to the first quarter of 2017. A reconciliation of gross to net revenues can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Form 10-Q for the quarterly period ended June 30, 2017.

Cost of goods sold was \$5.1 million in the second quarter of 2017 compared to \$4.0 million in the second quarter of 2016, an increase of approximately \$1.1 million or 28%, primarily due to a write-down of inventory which was forecasted to become obsolete due to expiration. .

Research and development expenses were \$3.1 million in the second quarter of 2017 compared to \$4.3 million in the second quarter of 2016, a decrease of \$1.2 million or 28%, due to the reduction in workforce that took place in the fourth quarter of 2016.

Selling, general and administrative expenses were \$18.6 million for the second quarter of 2017 compared to \$11.1 million for the same quarter of 2016, an increase of \$7.5 million or 68%. The increase in selling expense is primarily due to recruiting a MannKind-employee sales force and building the related commercial support.

The net loss for the second quarter of 2017 was \$35.3 million, or \$0.35 per share based on 99.9 million weighted average shares outstanding, compared to the net loss of \$30.0 million, or \$0.33 per share on 91.1 million weighted average shares outstanding in the second quarter of 2016.

Six Months Ended Results

For the six months ended June 30, 2017, total net revenue of \$5.2 million was comprised of \$2.7 million of Afrezza product net sales, \$1.8 million from the sales of surplus bulk insulin to a third party and \$0.6 million from the sale of certain oncology intellectual property.

Cost of goods sold was \$7.6 million for the six months ended June 30, 2017 compared to \$9.2 million for the same period in 2016, a decrease of approximately \$1.6 million or 17%, primarily due to a decrease in under-absorbed labor and overhead as a result of the reduction in the workforce that took place in the fourth quarter of 2016.

Research and development expenses were \$6.3 million for the six months ended June 30, 2017 compared to \$9.4 million for the same period in 2016, a decrease of \$3.1 million or 33%, due primarily to compensation expense resulting from the reduction in force in the fourth quarter of 2016.

Selling, general and administrative expenses were \$34.0 million for the six months ended June 30, 2017 compared to \$18.5 million for the same period in 2016, an increase of \$15.5 million or 84%, primarily due to increased selling and marketing activities associated with recruiting a MannKind-employee sales force and building the related commercial support.

The net loss for the six months ended June 30, 2017 was \$51.7 million, or \$0.53 per share based on 97.8 million weighted average shares outstanding, compared to the net loss of \$54.8 million, or \$0.62 per share on 88.4 million weighted average shares outstanding at June 30, 2016.

Cash and Cash Equivalents

Cash and cash equivalents at June 30, 2017 were \$43.4 million, compared to \$48.0 million at March 31, 2017. During the second quarter of 2017, we received net borrowings of \$19.4 million from the Mann Group.

Product Pipeline

The Company had a positive pre-IND meeting with the FDA during June 2017 and, as a result, will be advancing treprostinil Technosphere for the treatment of pulmonary arterial hypertension with the intention of filing an investigational new drug application by the end of 2017.

Conference Call

MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. To view and listen to the earnings call webcast, visit MannKind's website at <http://www.mannkindcorp.com> and click on the "Q2 2017 MannKind Earnings Conference Call" link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 44096373.

A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4409 6373#. A replay will also be available on MannKind's website for 14 days.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind's ability to directly commercialize pharmaceutical products. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, MannKind's ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Corporation and Subsidiaries
Condensed Consolidated Statement of Operation
(Unaudited)
(In thousands, except per share data)

| | <u>Three Months Ended June 30,</u> | | <u>Six Months Ended June 30,</u> | |
|-------------------------------------------------------------|------------------------------------|--------------------|----------------------------------|--------------------|
| | <u>2017</u> | <u>2016</u> | <u>2017</u> | <u>2016</u> |
| Revenues: | | | | |
| Net revenue - commercial product sales | \$ 1,548 | \$ - | \$ 2,745 | \$ - |
| Net revenue - collaboration | 63 | -- | 125 | -- |
| Revenue - other | <u>552</u> | <u>--</u> | <u>2,302</u> | <u>--</u> |
| Total revenues | <u>2,163</u> | <u>--</u> | <u>5,172</u> | <u>--</u> |
| Expenses: | | | | |
| Cost of goods sold | 5,086 | 4,045 | 7,635 | 9,213 |
| Research and development | 3,123 | 4,310 | 6,251 | 9,440 |
| Selling, general and administrative | 18,566 | 11,110 | 33,956 | 18,460 |
| Property and equipment impairment | 111 | -- | 111 | -- |
| (Gain) loss on foreign currency translation | <u>6,848</u> | <u>(341)</u> | <u>8,392</u> | <u>2,023</u> |
| Total expenses | <u>33,734</u> | <u>19,124</u> | <u>56,345</u> | <u>39,136</u> |
| Loss from operations | <u>(31,571)</u> | <u>(19,124)</u> | <u>(51,173)</u> | <u>(39,136)</u> |
| Other income (expense): | | | | |
| Change in fair value of warrant liability | 147 | (5,306) | 6,776 | (5,306) |
| Interest income | 58 | 26 | 114 | 41 |
| Interest expense on notes | (2,422) | (4,181) | (5,128) | (8,401) |
| Interest expense on note payable to principal stockholder | (721) | (721) | (1,435) | (1,443) |
| Loss on extinguishment of debt | (830) | -- | (830) | -- |
| Other income | <u>--</u> | <u>(653)</u> | <u>13</u> | <u>(586)</u> |
| Total other income (expense) | <u>(3,768)</u> | <u>(10,835)</u> | <u>(490)</u> | <u>(15,695)</u> |
| Loss before benefit for income taxes | (35,339) | (29,959) | (51,663) | (54,831) |
| Income tax benefit | <u>--</u> | <u>--</u> | <u>--</u> | <u>--</u> |
| Net loss | <u>\$ (35,339)</u> | <u>\$ (29,959)</u> | <u>\$ (51,663)</u> | <u>\$ (54,831)</u> |
| Net loss per share - basic and diluted | <u>\$ (0.35)</u> | <u>\$ (0.33)</u> | <u>\$ (0.53)</u> | <u>\$ (0.62)</u> |
| Shares used to compute basic and diluted net loss per share | <u>99,864</u> | <u>91,061</u> | <u>97,816</u> | <u>88,416</u> |

MANKIND CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

| | June 30, 2017 | December 31, 2016 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 43,384 | \$ 22,895 |
| Accounts receivable, net | 1,312 | 302 |
| Receivable from Sanofi | - | 30,557 |
| Inventory | 3,172 | 2,331 |
| Asset held for sale | - | 16,730 |
| Deferred costs from commercial product sales | 500 | 309 |
| Prepaid expenses and other current assets | 2,563 | 4,364 |
| Total current assets | 50,931 | 77,488 |
| Property and equipment - net | 27,920 | 28,927 |
| Other assets | 523 | 648 |
| Total assets | \$ 79,374 | \$ 107,063 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | |
| Current liabilities: | | |
| Accounts payable | \$ 6,541 | \$ 3,263 |
| Accrued expenses and other current liabilities | 9,076 | 7,937 |
| Facility financing obligation | 57,484 | 71,339 |
| Deferred revenue - net | 2,592 | 3,419 |
| Deferred payments from collaboration - current | 250 | 1,000 |
| Recognized loss on purchase commitments - current | 9,926 | 5,093 |
| Total current liabilities | 85,869 | 92,051 |
| Note payable to principal stockholder | 79,666 | 49,521 |
| Accrued interest - note payable to principal stockholder | - | 9,281 |
| Senior convertible notes | 27,649 | 27,635 |
| Recognized loss on purchase commitments - long term | 99,001 | 95,942 |
| Deferred payments from collaboration - long term | 625 | - |
| Warrant liability | 605 | 7,381 |
| Milestone rights liability and other liabilities | 7,202 | 8,845 |
| Total liabilities | 300,617 | 290,656 |
| Commitments and contingencies (Note 11) | | |
| Stockholders' deficit: | | |
| Undesignated preferred stock, \$0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2017 and December 31, 2016 | - | - |
| Common stock, \$0.01 par value - 140,000,000 shares authorized, 104,615,982 and 95,680,831 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively | 1,046 | 957 |
| Additional paid-in capital | 2,566,960 | 2,553,039 |
| Accumulated other comprehensive loss | (21) | (24) |
| Accumulated deficit | (2,789,228) | (2,737,565) |
| Total stockholders' deficit | (221,243) | (183,593) |
| Total liabilities and stockholders' deficit | \$ 79,374 | \$ 107,063 |
